Auswahl der wissenschaftlichen Literatur zum Thema „Preclinical oncology“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Inhaltsverzeichnis
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Preclinical oncology" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Preclinical oncology"
Kahn, Jenna, Philip J. Tofilon und Kevin Camphausen. „Preclinical models in radiation oncology“. Radiation Oncology 7, Nr. 1 (2012): 223. http://dx.doi.org/10.1186/1748-717x-7-223.
Der volle Inhalt der QuelleKumari, Rajendra. „Refining Preclinical Modeling in Oncology“. Genetic Engineering & Biotechnology News 33, Nr. 19 (November 2013): 34–35. http://dx.doi.org/10.1089/gen.33.19.14.
Der volle Inhalt der QuelleIbarrola-Villava, Maider, Andrés Cervantes und Alberto Bardelli. „Preclinical models for precision oncology“. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1870, Nr. 2 (Dezember 2018): 239–46. http://dx.doi.org/10.1016/j.bbcan.2018.06.004.
Der volle Inhalt der QuelleGardner, Eric E., und Charles M. Rudin. „Preclinical oncology — reporting transparency needed“. Nature Reviews Clinical Oncology 13, Nr. 1 (15.12.2015): 8–9. http://dx.doi.org/10.1038/nrclinonc.2015.216.
Der volle Inhalt der QuelleClézardin, Philippe, Ismahène Benzaïd und Peter I. Croucher. „Bisphosphonates in preclinical bone oncology“. Bone 49, Nr. 1 (Juli 2011): 66–70. http://dx.doi.org/10.1016/j.bone.2010.11.017.
Der volle Inhalt der QuelleThöni, C. „Preclinical research in oncology: Gender aspects“. memo - Magazine of European Medical Oncology 4, Nr. 4 (Dezember 2011): 217–20. http://dx.doi.org/10.1007/s12254-011-0295-y.
Der volle Inhalt der QuelleBOULEFTOUR, WAFA, BENOITE MERY, ELISE ROWINSKI, CHARLENE RIVIER, ELISABETH DAGUENET und NICOLAS MAGNE. „Cardio-Oncology Preclinical Models: A Comprehensive Review“. Anticancer Research 41, Nr. 11 (November 2021): 5355–64. http://dx.doi.org/10.21873/anticanres.15348.
Der volle Inhalt der QuelleWittenburg, Luke A., und Daniel L. Gustafson. „Optimizing preclinical study design in oncology research“. Chemico-Biological Interactions 190, Nr. 2-3 (April 2011): 73–78. http://dx.doi.org/10.1016/j.cbi.2011.01.029.
Der volle Inhalt der QuelleZumberg, Marc S., Virginia C. Broudy, Elizabeth M. Bengtson und Scott D. Gitlin. „Preclinical Medical Student Hematology/Oncology Education Environment“. Journal of Cancer Education 30, Nr. 4 (31.01.2015): 711–18. http://dx.doi.org/10.1007/s13187-014-0778-8.
Der volle Inhalt der QuelleHormuth, David A., Anna G. Sorace, John Virostko, Richard G. Abramson, Zaver M. Bhujwalla, Pedro Enriquez‐Navas, Robert Gillies et al. „Translating preclinical MRI methods to clinical oncology“. Journal of Magnetic Resonance Imaging 50, Nr. 5 (29.03.2019): 1377–92. http://dx.doi.org/10.1002/jmri.26731.
Der volle Inhalt der QuelleDissertationen zum Thema "Preclinical oncology"
Loskog, Angelica. „Immunogene Therapy of Bladder Carcinoma : A Preclinical Study“. Doctoral thesis, Uppsala universitet, Enheten för onkologi, 2002. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2637.
Der volle Inhalt der QuelleChaffee, Beth K. „Preclinical Modeling of Musculoskeletal Cancer“. The Ohio State University, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=osu1376844544.
Der volle Inhalt der QuelleVenugopal, Balaji. „Preclinical evaluation of a novel drug delivery system for cisplatin“. Thesis, University of Glasgow, 2012. http://theses.gla.ac.uk/4198/.
Der volle Inhalt der QuelleMartín, Liberal Juan Jesús. „Combination of cytotoxic agents and targeted therapy for the treatment of advanced sarcomas: preclinical background and early clinical development“. Doctoral thesis, Universitat de Barcelona, 2016. http://hdl.handle.net/10803/401753.
Der volle Inhalt der QuelleLos sarcomas son un grupo de tumores caracterizados por su mal pronóstico y la ausencia de tratamientos efectivos. La mediana de supervivencia de los pacientes afectos de sarcoma avanzado es de tan solo 1 año a pesar de recibir tratamiento. Por lo tanto, es necesario encontrar nuevas estrategias terapéuticas efectivas. Nuestra hipótesis es que la inhibición de la angiogénesis y de la vía de mTOR en sarcomas en combinación con agentes citotóxicos activos potencia la actividad anti tumoral de cada una de las estrategias terapéuticas por separado sin toxicidad significativa. Para confirmar dicha hipótesis realizamos dos ensayos clínicos fase I con experimentos preclínicos asociados que han sido publicados en revistas científicas internacionales. Artículo 1: Ensayo clínico fase I de sorafenib en combinación con ifosfamida en pacientes con sarcoma avanzado: un estudio del Grupo Español de Investigación en Sarcomas (GEIS). Este ensayo clínico fase I evaluó la seguridad, la farmacocinética, la toxicidad limitante de dosis, la dosis máxima tolerada y la dosis recomendada de la combinación de sorafenib más ifosfamida en pacientes con sarcoma avanzado. La dosis recomendada fue sorafenib 400 mg bid más ifosfamida 6 g/m2, un esquema que permite la administración de dosis activas de ambos fármacos. También se observaron signos preliminares de actividad antitumoral. Artículo 2: Ensayo clínico fase I y evaluación de la eficacia preclínica del inhibidor de mTOR sirolimus más gemcitabina en pacientes con tumores sólidos avanzados Llevamos a cabo un ensayo clínico fase I en pacientes con tumores sólidos avanzados para identificar la dosis recomendada, evaluar la PK, la actividad farmacodinámica y la eficacia antitumoral preclínica de la combinación de sirolimus y gemcitabina. La dosis recomendada fue sirolimus 5 mg al día más gemcitabina 800 mg/m2. Además, se observó actividad antitumoral en los modelos preclínicos de sarcoma, así como inhibición de la vía de mTOR.
Sambandam, Vaishnavi. „The Role of Hedgehog signaling in Hepatitis B virus X protein mediated hepatocellular carcinoma“. Diss., Temple University Libraries, 2014. http://cdm16002.contentdm.oclc.org/cdm/ref/collection/p245801coll10/id/292349.
Der volle Inhalt der QuellePh.D.
Hepatitis B virus encoded X protein (HBx) contributes centrally to the pathogenesis of hepatocellular carcinoma (HCC). Aberrant activation of the Hedgehog (Hh) pathway has been linked to cancer. Thus, experiments were designed to test the hypothesis that HBx contributes to HCC via activation of Hh signaling. HBx expression correlated with up-regulation of Hh markers in human liver cancer cell lines, in HBx transgenic mice that developed HCC and in liver samples from HBV infected patients with HCC. The findings in human samples provide clinical validation of those in the HBx transgenic mice (HBxTg), and underscore the relevance of these transgenic mice to disease pathogenesis. Further, blockade of Hh signaling inhibited HBx stimulation of cell migration, anchorage independent growth, HCC tumorigenesis in HBx transgenic mice and tumor growth in xenograft model. These results suggest that the ability of HBx to promote cancer is at least partially dependent upon Hh activation and that activation of Hh signaling appears to be important for the development of HBx associated HCC. HBx also activates pathways that stimulate downstream Hh signaling, such as PI3K/AKT and Ras/Raf/MEK, also referred as non-canonical Hh signaling. Upon canonical Hh inhibition, compensatory activation of these pathways was seen in the presence of HBx in liver cancer cell lines and in HBxTg mice. Individual inhibition of these pathways also down-regulated Gli2 expression in HBx positive cell lines. These data suggests that in addition to canonical Hh signaling, activation of PI3K/AKT and ERK pathways by HBx leads to up-regulation of Gli2 expression in HBV-mediated HCC. This work identifies Hh pathway inhibition as a therapeutic strategy to slow tumor development and this work could lead to combination therapies that target Hh, AKT and ERK pathways, which may prevent or delay the appearance/progression of HCC.
Temple University--Theses
Gullbo, Joachim. „Preclinical Development of New Alkylating Oligopeptides for Cancer Therapy“. Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3785.
Der volle Inhalt der QuelleJeon, Jae Yoon. „Preclinical and clinical development of kinase inhibitors in acute myeloid leukemia“. The Ohio State University, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=osu158699311567933.
Der volle Inhalt der QuelleKarlsson, Henning. „New preclinical strategies for characterization and development of anticancer drugs“. Doctoral thesis, Uppsala universitet, Cancerfarmakologi och beräkningsmedicin, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-330999.
Der volle Inhalt der QuelleRecasens, Zorzo Clara. „Preclinical evaluation of the antitumor activity of a new CXCR4 inhibitor: a novel therapeutic approach in diffuse large B-cell lymphoma“. Doctoral thesis, Universitat de Barcelona, 2018. http://hdl.handle.net/10803/663897.
Der volle Inhalt der QuelleLa activación constitutiva del receptor de quemocinas CXCR4 está asociada a la progresión tumoral, invasión y resistencia al tratamiento. En el linfoma difuso de células grandes (LDCG) la sobreexpresión de CXCR4 concede un peor pronóstico, pero la relevancia biológica de este receptor no se ha estudiado en profundidad. En esta tesis se ha evaluado un nuevo inhibidor de CXCR4 (IQS-01.01) en modelos preclínicos de LDCG. Usando tanto modelos in vitro como in vivo de LDCG se ha concluido 1) que la inhibición de CXCR4 en LDCG tiene un efecto antitumoral, 2) que IQS-01.01RS tiene mayores propiedades farmacológicas que el inhibidor de referencia, AMD3100 3) que el tratamiento con IQS-01.01RS reduce los niveles del oncogén MYC y 4) que la combinación de IQS-01.01 RS con el inhibido de BET, CPI203, confiere un efecto antitumoral sinérgico. Los resultados de esta tesis doctoral ponen en evidencia una cooperación entre MYC y CXCR4 en LDCG e indican que la inhibición de CXCR4 en combinación con un inhibidor de MYC es una terapia prometedora contra el LDCG.
Chakupurakal, Geothy. „Preclinical studies of adenovirus-specific T-cells for adoptive transfer to haemopoietic stem cell transplant recipients“. Thesis, University of Birmingham, 2011. http://etheses.bham.ac.uk//id/eprint/2883/.
Der volle Inhalt der QuelleBücher zum Thema "Preclinical oncology"
1954-, Adams Julian, Hrsg. Proteasome inhibitors in cancer therapy. Totowa, N.J: Humana Press, 2004.
Den vollen Inhalt der Quelle finden1954-, Adams Julian, Hrsg. Proteasome inhibitors in cancer therapy. Totowa, N.J: Humana Press, 2004.
Den vollen Inhalt der Quelle findenFiebig, H. H. Revelance Of Tumor Models For Anticancer Drug Development (CONTRIBUTIONS TO ONCOLOGY). Herausgegeben von H. H. Fiebig. Karger, 1999.
Den vollen Inhalt der Quelle findenKerr, David J., und Bruce C. Baguley. Anticancer Drug Development. Elsevier Science & Technology Books, 2001.
Den vollen Inhalt der Quelle findenAdams, Julian. Proteasome Inhibitors in Cancer Therapy. Humana Press, 2010.
Den vollen Inhalt der Quelle finden(Editor), Bruce C. Baguley, und David J. Kerr (Editor), Hrsg. Anticancer Drug Development. Academic Press, 2001.
Den vollen Inhalt der Quelle findenBuchteile zum Thema "Preclinical oncology"
Nimmagadda, Sridhar, Sagar Shelake und Martin G. Pomper. „Preclinical Experimentation in Oncology“. In Radiopharmaceutical Chemistry, 569–82. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-98947-1_33.
Der volle Inhalt der QuelleSeo, Youngho, He Jiang und Benjamin L. Franc. „Preclinical SPECT and SPECT/CT“. In Molecular Imaging in Oncology, 193–220. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-10853-2_6.
Der volle Inhalt der QuelleKalen, Joseph D., und James L. Tatum. „Small Animal Imaging in Oncology Drug Development“. In Image Fusion in Preclinical Applications, 101–15. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-02973-9_5.
Der volle Inhalt der QuelleFranc, Benjamin L., Youngho Seo, Robert Flavell und Carina Mari Aparici. „Preclinical SPECT and SPECT-CT in Oncology“. In Molecular Imaging in Oncology, 359–404. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-42618-7_11.
Der volle Inhalt der QuelleWolf, Gunter, und Nasreddin Abolmaali. „Preclinical Molecular Imaging Using PET and MRI“. In Molecular Imaging in Oncology, 257–310. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-10853-2_9.
Der volle Inhalt der QuelleReichardt, Wilfried, und Dominik von Elverfeldt. „Preclinical Applications of Magnetic Resonance Imaging in Oncology“. In Molecular Imaging in Oncology, 405–37. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-42618-7_12.
Der volle Inhalt der QuelleZschaeck, S., und M. Beck. „Whole-Body Hyperthermia in Oncology: Renaissance in the Immunotherapy Era?“ In Water-filtered Infrared A (wIRA) Irradiation, 107–15. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-92880-3_8.
Der volle Inhalt der QuelleRojiani, Mumtaz V., und Amyn M. Rojiani. „Morphologic Manifestations of Vascular-disrupting Agents in Preclinical Models“. In Vascular-Targeted Therapies in Oncology, 81–94. Chichester, UK: John Wiley & Sons, Ltd, 2006. http://dx.doi.org/10.1002/0470035439.ch5.
Der volle Inhalt der QuelleChopra, Rajesh, und Florence I. Raynaud. „Preclinical Studies to Enable First in Human Clinical Trials“. In Phase I Oncology Drug Development, 45–69. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-47682-3_3.
Der volle Inhalt der QuelleBuck, Andreas K., Florian Gärtner, Ambros Beer, Ken Herrmann, Sibylle Ziegler und Markus Schwaiger. „Preclinical and Clinical Tumor Imaging with SPECT/CT and PET/CT“. In Drug Delivery in Oncology, 247–88. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2011. http://dx.doi.org/10.1002/9783527634057.ch9.
Der volle Inhalt der QuelleKonferenzberichte zum Thema "Preclinical oncology"
Selt, F., J. Kiss, J. Gronych, DTW Jones, T. Brummer, AE Kulozik, SM Pfister, T. Milde und O. Witt. „Preclinical model development for pilocytic astrocytoma“. In 26th Annual Meeting of the working group “Experimental Neuro-Oncology”. Georg Thieme Verlag KG, 2017. http://dx.doi.org/10.1055/s-0037-1607402.
Der volle Inhalt der QuelleXue, Jia, Xiaobo Chen, Xiaoyu An, Jingjing Wang, Henry Li und Sheng Guo. „40 NGS-based immunology panel: applications in preclinical immuno-oncology research“. In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.0040.
Der volle Inhalt der QuelleVasciaveo, Alessandro, Min Zou, Juan Arriaga, Andrea Califano und Cory Abate-Shen. „Abstract 822: OncoLoop: Closing the loop between patient-centered drug discovery and preclinical testing in precision-oncology“. In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-822.
Der volle Inhalt der QuelleKrueger, Sarah, Thomas Dailey, Kevin Guley und Maryland Franklin. „Abstract 4712: Image-guided focal irradiation in syngeneic preclinical oncology mouse models“. In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-4712.
Der volle Inhalt der QuelleStecklum, Maria, Annika Wulf-Goldenberg, Magdalena Paterka, Bernadette Brzezicha, Iduna Fichtner und Jens Hoffmann. „Abstract A006: Preclinical tumor models in humanized mice for translational immuno-oncology research“. In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 26-30, 2017; Philadelphia, PA. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1535-7163.targ-17-a006.
Der volle Inhalt der QuelleLee, Joon Sang, Shannon McGrath, Emma Wang, Maximilian Rogers-Grazado, Yu-an Zhang, Natalia Malkova, Jack Pollard und Alexei Protopopov. „Abstract 174: Genomic cytometry characterization of preclinical models for development of immune-oncology therapeutics“. In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-174.
Der volle Inhalt der QuelleSachsenmeier, Kris F., Nazzareno Dimasi, Qihui Huang, Erin Sult, Binyam Bezabeh, Ryan Fleming, Carl Hay et al. „Abstract 4635: The avidity hypothesis: comparing bispecific and monospecific antibodies in preclinical oncology models.“ In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-4635.
Der volle Inhalt der QuelleStecklum, Maria, Annika Wulf-Goldenberg, Bernadette Brzezicha, Konrad Klinghammer, Korinna Jöhrens, Wolfgang Walther und Jens Hoffmann. „Abstract 2713: Preclinical models for translational immuno-oncology research: patient-derived xenografts on humanized mice“. In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-2713.
Der volle Inhalt der QuelleIbsen, Eric M., und Jeffrey Kumer. „Abstract 3498: A systematic approach to evaluate and select preclinical study workflow software applications for oncology“. In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-3498.
Der volle Inhalt der QuelleBrzezicha, Bernadette, Michael Becker, Maria Stecklum, Teresia Conrad, Martin Janz, Aitomi Bittner, Clemens Schmitt, Ulrich Keilholz und Jens Hoffmann. „Abstract 1069: New panel of patient derived lymphoma xenografts (PDX) for preclinical research and immune oncology“. In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-1069.
Der volle Inhalt der Quelle